In an exciting breakthrough for respiratory medicine, researchers at Mass General Brigham have developed a new gene therapy that can be delivered using a simple nasal spray. This innovative treatment targets diseases affecting the lungs and airways, offering hope for patients suffering from conditions such as pulmonary fibrosis and viral infections like COVID-19.
The key to this advance is a modified version of adeno-associated viruses (AAV), known as AAV.CPP.16. These viruses serve as delivery vehicles for gene therapy, helping to transport therapeutic molecules directly to specific areas in the body. The research team, including senior author Dr. FengFeng Bei, discovered that the new AAV.CPP.16 variant efficiently targets lung cells—something previous versions struggled with.
In preclinical tests involving animal models, AAV.CPP.16 outperformed earlier AAV types such as AAV6 and AAV9. This new delivery system showed improved results in both cultured cells and living subjects, including mice and non-human primates.
Dr. Bei stated, “We initially engineered AAV.CPP.16 to enter the central nervous system, but we found it also effectively targets the lungs. This discovery led us to explore its potential for treating respiratory diseases.”
In their experiments, the researchers used AAV.CPP.16 to deliver gene therapy that could prevent scarring in the lungs associated with pulmonary fibrosis. Additionally, they tested the therapy’s efficacy in combating the SARS-CoV-2 virus in mouse models of COVID-19, demonstrating its potential to inhibit virus replication.
While further research is needed to fully understand the implications of these findings, Dr. Bei expressed optimism about the potential of intranasal AAV.CPP.16 as a tool for targeting lung diseases.
This development marks a significant step forward in the field of gene therapy, particularly for conditions that affect breathing and lung function. As researchers continue to analyze the effectiveness and safety of this new therapy, patients and healthcare providers may soon have more options for treating serious respiratory disorders.
The team’s findings were published in the peer-reviewed journal *Cell Reports Medicine*, highlighting the importance of ongoing innovation in medical treatment.
